Lucinactant 175 mg/kg
KL4-BPD-01
Phase 2 small_molecule terminated
Quick answer
Lucinactant 175 mg/kg for Respiratory Distress Syndrome, Newborn is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).
Program details
- Company
- WINDTREE THERAPEUTICS INC /DE/
- Indication
- Respiratory Distress Syndrome, Newborn
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated